A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis - INCB 54707-306

开始日期2025-02-10

申办/合作机构

Incyte Corp.

NCT06516952

/ Recruiting临床3期

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis

The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.

开始日期2024-10-10

申办/合作机构

Incyte Corp.

100 项与 Povorcitinib 相关的临床结果

登录后查看更多信息

100 项与 Povorcitinib 相关的转化医学

登录后查看更多信息

100 项与 Povorcitinib 相关的专利（医药）

登录后查看更多信息

项与 Povorcitinib 相关的文献（医药）

2024-06-01·JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT

Chronic Prurigo

Review

作者: Zeidler, Claudia ; Steinbrink, Kerstin ; Müller, Svenja ; Ständer, Sonja ; Thünemann, Julia

Summary:

Chronic prurigo (CPG) is a neuroinflammatory dermatosis characterized by prolonged pruritus lasting more than 6 weeks, pruriginous skin lesions, and repeated scratching.Patients with CPG suffer significantly from psychological distress and a marked impairment in their quality of life. The most common subtype of CPG is chronic nodular prurigo (CNPG, also called prurigo nodularis).In addition to the clinical features of CPG and the burden of disease, this CME article provides an overview of the significant advances in understanding the pathophysiology, including the associated therapeutic options for CPG. Dupilumab is the first approved therapy for moderate and severe CNPG to date from the European Medicines Agency (EMA) and the US Food & Drug Administration (FDA). It also highlights other agents currently being studied in Phase II and Phase III clinical, randomized, placebo‐controlled trials. These include biologics such as nemolizumab (anti‐IL‐31‐RA‐mAb), vixarelimab/KPL‐716 (anti‐Oncostatin‐M receptor β‐mAb), and barzolvolimab/CDX‐0159 (anti‐KIT‐mAb), as well as Janus kinase inhibitors such as povorcitinib/INCB054707 and abrocitinib, and opioid modulators such as nalbuphine.

2024-05-17·BRITISH JOURNAL OF DERMATOLOGY

Prurigo nodularis: new insights into pathogenesis and novel therapeutics

Review

作者: Ma, Emily ; Cornman, Hannah L ; Kwatra, Shawn G ; Liao, Viviane

Lay Summary:

Prurigo nodularis (PN) is a chronic skin condition featuring extremely itchy nodules on the skin of the legs, arms and trunk of the body. PN affects approximately 72 per 100 000 people and the severe itch associated with the condition can negatively impact a person’s sleep, work and social life. However, the cause of PN remains unclear.Current understanding of PN is based on imbalances in the immune system leading to widespread inflammation as well as dysregulation of the nerves in the skin. Immune molecules released from T cells [such as interleukin (IL)-4, -13, -31, -17, -22 and -31] increase systemic inflammation and are elevated in people with PN. Activated inflammatory cells (such as mast cells or eosinophils) may also release factors that promote inflammation, itch and neural changes within the skin. Neural dysregulation in PN features a lower density of itch-sensing nerve fibres in the epidermis (upper layer of the skin) and a higher density of itch-sensing nerve fibres in the dermis (lower layer of the skin). Because the pathogenesis of PN is not fully understood, the therapies available for PN have had limited success in reducing itch and nodules.The only drug currently approved for PN in the USA and Europe is dupilumab, an IL-4Rα inhibitor that blocks signalling through IL-4 and IL-13, which is undergoing post-marketing surveillance. Other new drugs are being assessed in various phases of clinical trials, including nemolizumab, vixarelimab, barzolvolimab, ruxolitinib, abrocitinib, povorcitinib and nalbuphine.

2024-03-01·Journal of the American Academy of Dermatology

Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study

Article

作者: Kimball, Alexa B ; Brown, Kurt ; Wang, Annie ; Porter, Martina L ; Kirby, Joslyn S ; Okun, Martin M ; Alavi, Afsaneh ; Bechara, Falk G ; Zouboulis, Christos C ; Bibeau, Kristen B ; Santos, Leandro L

BACKGROUND:

Janus kinase 1 inhibition may alleviate hidradenitis suppurativa (HS)-associated inflammation and improve symptoms.

OBJECTIVE:

To assess efficacy and safety of povorcitinib (selective oral Janus kinase 1 inhibitor) in HS.

METHODS:

This placebo-controlled phase 2 study randomized patients with HS 1:1:1:1 to receive povorcitinib 15, 45, or 75 mg or placebo for 16 weeks. Primary and key secondary end points were mean change from baseline in abscess and inflammatory nodule count and percentage of patients achieving HS Clinical Response at week 16.

RESULTS:

Of 209 patients randomized (15 mg, n = 52; 45 mg, n = 52; 75 mg, n = 53; placebo, n = 52), 83.3% completed the 16-week treatment. At week 16, povorcitinib significantly reduced abscess and inflammatory nodule count from baseline (least squares mean [SE] change: 15 mg, -5.2 [0.9], P = .0277; 45 mg, -6.9 [0.9], P = .0006; 75 mg, -6.3 [0.9], P = .0021) versus placebo (-2.5 [0.9]). More povorcitinib-treated patients achieved HS Clinical Response at week 16 (15 mg, 48.1%, P = .0445; 45 mg, 44.2%, P = .0998; 75 mg, 45.3%, P = .0829) versus placebo (28.8%). A total of 60.0% and 65.4% of povorcitinib- and placebo-treated patients had adverse events.

LIMITATIONS:

Baseline lesion counts were mildly imbalanced between groups.

CONCLUSION:

Povorcitinib demonstrated efficacy in HS, with no evidence of increased incidence of adverse events among doses.

项与 Povorcitinib 相关的新闻（医药）

2025-03-19

·美通社

康哲药业（00867）发布2024年度业绩：聚焦创新与专科突破重塑增长动能

深圳 2025年3月19日 /美通社/ -- 3月17日，康哲药业发布2024年度业绩，公司全年实现营业收入人民币74.69亿元，同比下降6.8%；若全按药品销售收入计算，营业额为人民币86.22亿元，同比下降9.0%；实现净利润人民币16.13亿元，剔除相关资产减值损失计提后的正常化净利润为人民币17.14亿元。公告显示，公司业绩下滑主要受国采执行影响，三款未中标原研药2024年收入同比下降28.8%至人民币26.91亿元（全按药品销售收入计算）。然而，对于公司而言，2024年既是挑战中的"重塑之年"，更是光芒初现的"突破之年"。公司整体业绩虽正经历短期阵痛，但独家药、创新药发展却不乏亮点，潜力已初步显现。公司2024年全按药品销售收入计算的独家产品及创新产品营收达人民币45.51亿元，同比增长4.1%，占总营业额的比重达到52.8%。本年度公司累计5款创新药进入商业化，但均处于早期市场导入阶段，未来随着已上市创新药逐步铺开大规模临床应用、快速放量，以及储备优质创新管线源源不断获批上市，公司将进入由独家药、创新药驱动的高质量、可持续发展新周期。公告显示，2024年康哲药业递交了重磅白癜风治疗创新药芦可替尼乳膏等2款新药的中国NDA，新增3项创新合作、3款医美产品合作。截至2024年底，公司已储备的短、中、长期创新管线总计近40项。此外，公司东南亚业务正蓄势待发，本年度已推动超过 5 款创新药递交上市注册申请，且联营公司的新加坡工厂前序准备工作基本完成，即将全面开展药品CDMO、销售推广业务，培育第二增长曲线。产品力为核心夯实创新增长引擎作为深耕医药市场三十余年、已推动多款在售药品取得领先市场地位的药品商业化龙头，康哲药业在布局创新药时也秉持着敏锐的市场洞察，以一线需求指导立项，优选全球FIC、BIC创新药，其需符合"三好品种"筛选标准：具有学术差异化优势、较大市场潜力与良好竞争格局、及综合投资回报率高。从公司已上市的创新药来看，5款产品或是较市场既有品种有明显差异化优势，或在细分领域填补了市场空白，因而能为患者提供有价值的创新治疗方案。举例来说，用于慢性肾脏病（CKD）患者降磷的维福瑞（蔗糖羟基氧化铁咀嚼片）是经中国NMPA批准上市的首个铁基-非钙磷结合剂，并填补了国内12-18岁CKD4-5期或接受透析治疗的CKD患儿的降磷治疗用药空白，根据全球多项临床研究、真实世界研究资料（如发表在学术期刊International Urology and Nephrology、Clinical Nephrology的文献）及产品中国说明书，与其他磷结合剂相比，服用维福瑞的患者平均日服药片数减少了约50%，血磷达标率可提高95%；而益路取（替瑞奇珠单抗注射液）是一款靶向IL-23p19亚基、治疗中重度斑块状银屑病的创新生物制剂，维持期只需每3个月给药一次，凭借其优异的长期疗效、便捷的用药周期和较好的安全性，有助于提升患者依从性。公司以优异的产品力为核心，并借助多年积累的丰富学术资源、推广经验，将有望实现已上市产品市场渗透力和品牌影响力的快速提升。公司目前处于NDA审评阶段、有望于2025年上市的2款创新药，芦可替尼乳膏、德昔度司他片，均被认为具备高市场潜力。根据公告，芦可替尼乳膏是截至目前美国FDA以及欧洲EMA批准的首个也是唯一一个局部 JAK 抑制剂白癜风复色产品，若成功上市，将为国内超千万深受困扰、无对症药物可用的白癜风患者带来治疗曙光。德昔度司他片用于治疗非透析成人CKD患者的贫血，并采用口服给药方式，中国III期临床试验结果显示，其在有效性、安全性和耐受性方面均表现良好。数据显示，我国CKD患者约有1.32亿，贫血是其常见并发症之一，产品上市后有望进一步满足CKD患者的贫血治疗需求。此外，公司已储备的、将于未来2至4年内获批上市的创新管线中，也有多款市场关注度高、业内评估有望成为FIC与BIC的大品种，如用于卒中治疗的注射用Y-3 、高选择性小分子口服JAK1抑制剂povorcitinib（非节段型白癜风、化脓性汗腺炎）、URAT1抑制剂ABP - 671（痛风）、抗IL-4Rα人源化单抗注射液MG-K10（特应性皮炎）、口服改良型新药ZUNVEYL（阿尔茨海默病）等，可有力支撑公司未来业绩的持续增长。值得关注的是，康哲药业始终坚持"合作开发+自主研发"并举的高效创新路径，重视研发资源投入效益最大化。2018年至2024年，公司累计研发开支为人民币43.5亿元，占同期全按药品销售收入比重为7.6%，其中费用化研发投入为人民币8.8亿元，占同期全按药品销售收入的1.5%。公司通过较为审慎的研发投入，实现多个优质创新产品的成功立项、临床开发与上市，创新投入产出效率极高。此外，2024年底公司银行结余及现金达人民币37.07亿元，为持续加码创新、深耕前沿领域提供了充足保障。专科聚焦强化商业化体系赋能产品价值释放强产品力与高效商业化能力协同发力，是康哲药业保持竞争优势的关键。康哲药业持续优化专科业务聚焦的商业化体系，形成以心脑血管/消化、皮肤/医美、眼科为核心的专科深耕格局，已积累丰富的专业推广网络和学术平台，为创新产品的成功商业化保驾护航。 2021年起独立运营的皮肤医美业务公司"康哲美丽"，正成长为中国领先、专业聚焦皮肤健康的创新型医药企业。康哲美丽已构建起以皮肤处方药为核心，并涵盖皮肤学级护肤品、轻医美产品的全产品矩阵。截至2024年底，其皮肤处方产品组合已全面覆盖白癜风、银屑病、AD、静脉炎、静脉曲张及化脓性汗腺炎等多种皮肤疾病；皮肤学级护肤品方面，专研敏感肌养护的"禾零舒缓产品系列"进一步完善，并新增"喜辽妥®壬二酸产品系列"，为痘肌修护提供全套解决方案；轻医美业务方面，童颜针中国注册申请已获受理，并引入少女针、微晶瓷、脱细胞基质植入剂三款处于中国注册性临床阶段的再生类产品，进一步完善轻医美产品线。康哲美丽以多元的皮肤健康与美学产品矩阵，为不同皮肤健康需求人群提供全面、综合解决方案。同一时期开始独立运营的眼科业务公司"康哲维盛"则专注于眼科处方药、医疗器械及耗材的开发与商业化。在中国，眼病患者数量庞大，且人口增长和老龄化导致眼科疾病负担显著上升。康哲维盛借助眼科领域专业产品组合、广泛的网络及渠道资源等，持续巩固产品品牌力及学术地位，致力于成为中国领先的眼科药械公司。截至2024年底，康哲药业拥有约4,700名市场及推广人员，推广网络覆盖全国超5万家医院及医疗机构、约30万家零售药店。依托覆盖广泛的推广网络、执行高效的推广团队，公司围绕已上市创新药和核心独家产品，动态优化市场策略、推动真实世界研究及上市后临床研究，持续积累学术证据，强化产品学术影响力并加速转化为市场价值。同时，本年度内公司强化院外市场覆盖深度与广度，并通过线上线下融合、多渠道协同，实现院外引流与患者获益的双向提升。以东南亚为起点培育海外业务第二增长曲线在深耕中国市场的同时，康哲药业加快国际化步伐，以东南亚为起点，借助当地对高性价比医药产品需求迅速增长这一有利契机，积极培育海外业务增长引擎，为公司长期、可持续增长注入新的动力。 2024年，东南亚业务公司"康联达健康"结合区域特征与疾病谱特点，精准规划产品组合与商业化路径，多款产品的上市注册取得阶段性进展，为后续市场推广与销售落地奠定基础。本年度内，康联达健康获得创新产品povorcitinib（选择性小分子口服JAK1抑制剂，有望为相关自身免疫性和炎症性皮肤病患者带来新的治疗选择）东南亚十一国的独家许可权利。同时，康联达健康亦积极推进芦可替尼乳膏、益路取、莱芙兰、维图可、维福瑞等多款创新产品在东南亚及/或港澳台地区市场的上市注册工作。其中，芦可替尼乳膏已于中国澳门、中国香港获批上市，用于治疗白癜风；并已于新加坡、中国台湾市场递交注册申请。此外，康联达健康与君实生物合作的特瑞普利单抗（抗PD-1单抗）也于本年度内递交了马来西亚、菲律宾、印尼、泰国、越南市场的注册申请。 CDMO业务方面，康哲药业联营公司PharmaGend位于新加坡大士的生产工厂已取得美国FDA的GMP认证，并顺利完成新加坡HSA现场审计，将为全球药企提供CDMO服务，同时也为康哲药业海外生产的供应链安全提供有力保障。站在新征程的起点，康哲药业以变应变、向新而行，坚定执行"创新驱动、效率优先、专科突破、全球布局"战略，重塑增长曲线，以更加多元、更有韧性的业务格局，迈向高质量发展的新阶段，将为患者提供更多优质治疗选择，为股东创造长期稳定回报。康哲药业免责与前瞻性声明本新闻无意向您做任何产品的推广，非广告用途。本新闻不对任何药品和医疗器械和/或适应症作推荐。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。医疗卫生专业人士作出的任何与治疗有关的决定应根据患者的具体情况并遵照药品说明书。由康哲药业编制的此新闻不构成购买或认购任何证券的任何要约或邀请，不形成任何合约或任何其他约束性承诺的依据或加以依赖。本新闻由康哲药业根据其认为可靠之资料及数据编制，但康哲药业并无进行任何说明或保证、明述或暗示，或其他表述，对本新闻内容的真实性、准确性、完整性、公平性及合理性不应加以依赖。本新闻中讨论的若干事宜可能包含涉及康哲药业的市场机会及业务前景的陈述，该等陈述分别或统称为前瞻性声明。该等前瞻性声明并非对未来表现的保证，存在已知及未知的风险、不明朗性及难以预知的假设。康哲药业并不采纳本新闻包含的第三方所做的任何前瞻性声明及预测，康哲药业对该等第三方声明及预测不承担责任。

上市批准财报

2025-03-17

·FierceBiotech

Incyte posts phase 3 skin condition wins but details disappoint, sinking stock

While Incyte called the data positive, investors were unconvinced and sent the biotech’s share price down.\n Incyte has delivered a pair of pivotal wins for an oral JAK inhibitor in an inflammatory skin condition. But with the placebo-adjusted response rate down on phase 2, the results drew unfavorable comparisons to rival data and triggered a 15% drop in the biotech’s share price. The JAK1 inhibitor, povorcitinib, could offer an oral alternative to biologics in multiple indications and, if approved, partly offset the loss of exclusivity of Incyte\'s JAKi Jakafi later this decade. Incyte took the candidate into phase 3 trials in the skin condition hidradenitis suppurativa (HS) after seeing (PDF) placebo-adjusted response rates of up to 27.7% in a mid-stage study. Asked by analysts at recent investor events, Incyte executives declined to name the number they were targeting in the phase 3 trials but did say they expected to see a profile that is consistent with the earlier trial. The primary endpoints looked at the number of patients who had a 50% or greater reduction in total abscess and inflammatory nodule count with no increase in abscess or draining tunnel count. In the first study, around 40% of patients on both the low and high dose met the criteria, versus around 30% on placebo. The drug and placebo figures in the second trial were around 42% and 29%, respectively. Adjusted for placebo, the response rates at the low and high dose were 10.5% and 10.9%, respectively, in the first trial. The figure for both doses was 13.7% in the second trial. In the earlier phase 2 trial, Incyte reported placebo-adjusted results of 17.3% and 27.7%, respectively, at the low and high doses used in the pivotal studies. Incyte saw higher placebo-adjusted results in a predefined subgroup of phase 3 patients who previously took a biologic. The biotech also found more people on povorcitinib had a 75% or greater improvement, experienced a reduction in flares and reported a more than three-point improvement on a pain scale. The overall safety profile of povorcitinib was consistent with previous data, according to Incyte.While the biopharma called the data positive, investors were unconvinced and sent the biotech’s share price down around 15% to just $58 in early premarket trading. The drop may reflect unfavorable comparisons between the phase 3 data and both Incyte’s midphase results and the evidence on rival biologics. UCB won approval for Bimzelx in HS after linking the biologic to placebo-adjusted response rates of 19% and 20% after 16 weeks in two phase 3 trials. Novartis’ biologic Cosentyx is also approved in the indication. Povorcitinib has the advantage of oral administration but the data leave scope to question the size of the opportunity that will be open to the small molecule.

临床结果临床3期临床2期上市批准

2025-03-17

·Endpoints

Incyte's stock sinks as pivotal skin disease data disappoint

Incyte’s topline pivotal data for its oral therapy for a painful inflammatory skin condition appear somewhat disappointing, with efficacy falling short of analysts’ expectations and in comparison with marketed drugs like UCB’s Bimzelx. The company’s shares $INCY fell about 10% on Monday morning. Incyte said Monday that the STOP-HS1 and STOP-HS2 studies of povorcitinib met their primary endpoints in patients with moderate-to-severe hidradenitis suppurativa (HS). After three months of treatment, significantly more patients given the JAK1 inhibitor than those given placebo had a reduction of at least 50% in the number of abscesses and inflammatory nodules, with no increase in abscess or draining tunnel count. This measure is known as HiSCR50. But the improvements over placebo were not as extensive as some had hoped. With the lower dose of povorcitinib — 45 mg once daily — the HiSCR50 delta was 10.5 percentage points in STOP-HS1 and 13.7 points in STOP-HS2. The differences versus placebo seen with the higher dose — 75 mg per day — were almost identical. That’s an odd finding, since a higher dose would be expected to work better. “We’ll have to wait for longer-term follow-up to see if there’s a separation of the 45 and 75 [mg doses],” Incyte head of R&D Pablo Cagnoni said during an analyst call to discuss the data. He added that Incyte plans to provide more data on this point later this year. Incyte also said the drug’s efficacy was better in patients who had previously been treated with biologics. Here the deltas over placebo were larger, but the p-value for the difference between the 45 mg dose and placebo in the HS-1 trial was 0.096, missing the generally accepted threshold for significance. William Blair analysts pointed out that the data came in well below the Phase 2 results, which showed placebo-adjusted HiSCR50 response rates of 18 to 28 percentage points. They added that even on an absolute basis, the Phase 3 HiSCR50 response rates for povorcitinib were markedly lesser than those seen in Phase 2. Incyte intends to wait for further data from the trial before seeking approval for the pill, and it’s aiming for an NDA submission at the end of this year or early next year. The Phase 3 data might be good enough for approval, with Incyte saying on the call that it believes regulators will greenlight povorcitinib for both biologic-naïve and -experienced patients. But doctors might have little reason to prescribe the pill when several approved injected drugs still look more effective. For example, in the pivotal HS trials for Bimzelx, the HiSCR50 delta was 19 to 26 percentage points. This was after four weeks of treatment, which is slightly longer than Incyte’s STOP-HS1 and STOP-HS2 trials, but the effect size is much greater. Another competitor is not far behind. There are high expectations for the pivotal data on MoonLake Immunotherapeutics’ antibody sonelokimab in HS. Those data should be revealed in the third quarter of this year.

临床结果临床3期临床2期免疫疗法

100 项与 Povorcitinib 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
结节性痒疹	临床3期	美国	Incyte Corp.	2024-10-10
结节性痒疹	临床3期	日本	Incyte Corp.	2024-10-10
结节性痒疹	临床3期	阿根廷	Incyte Corp.	2024-10-10
结节性痒疹	临床3期	澳大利亚	Incyte Corp.	2024-10-10
结节性痒疹	临床3期	奥地利	Incyte Corp.	2024-10-10
结节性痒疹	临床3期	比利时	Incyte Corp.	2024-10-10
结节性痒疹	临床3期	保加利亚	Incyte Corp.	2024-10-10
结节性痒疹	临床3期	加拿大	Incyte Corp.	2024-10-10
结节性痒疹	临床3期	智利	Incyte Corp.	2024-10-10
结节性痒疹	临床3期	捷克	Incyte Corp.	2024-10-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05620836 \| NCT05620823 (STOP-HS2, Company_Website) 人工标引	临床3期	化脓性汗腺炎	-	Povorcitinib 45 mg (STOP-HS1)	繭蓋齋廠鏇積鏇顧夢壓(膚顧顧窪鹹壓簾齋憲網) = 糧鹽網醖窪襯衊襯繭願鏇選鑰齋構膚壓遞艱窪 (積顧餘鏇觸鹹願齋構蓋 ) 达到更多	积极	2025-03-17
				Povorcitinib 75 mg (STOP-HS1)	繭蓋齋廠鏇積鏇顧夢壓(膚顧顧窪鹹壓簾齋憲網) = 衊鑰遞繭餘獵蓋鹹襯襯鏇選鑰齋構膚壓遞艱窪 (積顧餘鏇觸鹹願齋構蓋 ) 达到更多
NCT05061693 (CTgov)	临床2期	结节性痒疹	146	placebo (Placebo)	蓋膚夢網夢糧遞壓簾積 = 壓繭廠築觸鑰簾襯夢醖襯衊鬱網遞顧顧製選廠 (網遞製顧簾鏇獵鹹鹹蓋, 醖製窪構觸選顧觸製鑰 ~ 觸鬱醖鹽襯齋鏇鏇餘築) 更多	-	2024-08-27
				Povorcitinib (Povorcitinib 15 mg)	蓋膚夢網夢糧遞壓簾積 = 鑰築憲積蓋膚餘襯鏇憲襯衊鬱網遞顧顧製選廠 (網遞製顧簾鏇獵鹹鹹蓋, 鬱餘壓糧鹽顧簾觸餘簾 ~ 繭憲鑰蓋醖鹹襯衊鑰膚) 更多
NCT04818346 (AAD2024) 人工标引	临床2期	-	171	Povorcitinib (age≤40 years)	鬱襯願憲製構餘簾範網(淵齋顧艱鬱壓鬱壓蓋鑰) = 膚襯觸顧艱膚蓋顧艱遞蓋夢窪獵夢壓觸壓遞餘 (鑰遞夢蓋窪夢淵製獵襯 )	积极	2024-03-10
				Povorcitinib (age>40 years)	鬱襯願憲製構餘簾範網(淵齋顧艱鬱壓鬱壓蓋鑰) = 遞鏇鏇衊築製窪糧願鏇蓋夢窪獵夢壓觸壓遞餘 (鑰遞夢蓋窪夢淵製獵襯 )
NCT05061693 (Corporate Publications) 人工标引	临床2期	结节性痒疹	146	Povorcitinib 15 mg	積窪構憲網襯蓋齋齋顧(壓糧獵蓋觸鹹艱窪餘壓) = 築遞鑰構窪範鹽窪獵築淵膚夢選壓糧遞網憲願 (觸襯觸壓窪構選艱衊構 ) 达到更多	积极	2024-03-10
				Povorcitinib 45 mg	積窪構憲網襯蓋齋齋顧(壓糧獵蓋觸鹹艱窪餘壓) = 蓋鹽鏇獵醖壓鹹觸範簾淵膚夢選壓糧遞網憲願 (觸襯觸壓窪構選艱衊構 ) 达到更多
NCT04818346 (Corporate Publications) 人工标引	临床2期	非节段型白癜风	171	povorcitinib15-to-75 mg	衊鏇艱網積壓鹹鏇艱構(糧鬱鏇製醖鹽願蓋夢窪) = 夢願齋齋鹹繭餘襯顧觸窪糧選築壓積獵願鹹艱 (鑰顧鬱廠廠選築壓構膚 ) 更多	积极	2023-10-11
				povorcitinib45 mg	衊鏇艱網積壓鹹鏇艱構(糧鬱鏇製醖鹽願蓋夢窪) = 淵衊艱艱築選顧鏇鹽淵窪糧選築壓積獵願鹹艱 (鑰顧鬱廠廠選築壓構膚 ) 更多
EADV2023	临床2期	-	209	Povorcitinib 15 mg	鹹願鬱構顧積遞蓋餘觸(遞築壓醖鬱顧選廠範獵) = 積鑰範衊醖夢範鏇膚網選窪鏇簾範簾壓範簾鏇 (遞鏇蓋壓鹹鹽築構廠鑰 )	-	2023-10-11
				Povorcitinib 45 mg	鹹願鬱構顧積遞蓋餘觸(遞築壓醖鬱顧選廠範獵) = 積膚鏇醖襯願築築製憲選窪鏇簾範簾壓範簾鏇 (遞鏇蓋壓鹹鹽築構廠鑰 )
NCT04818346 (phase 2b, EADV2023)	临床2期	白癜风 Fitzpatrick skin types I - III	171	Povorcitinib 15 mg	積齋觸顧膚觸齋範蓋壓(繭鹹繭築淵鏇餘廠膚願) = 餘鬱構壓願餘艱鑰願淵餘選淵鹹築淵觸艱襯齋 (願鑰鬱構網選構窪製餘 )	积极	2023-10-11
				Povorcitinib 45 mg	積齋觸顧膚觸齋範蓋壓(繭鹹繭築淵鏇餘廠膚願) = 鏇壓網窪鹽壓醖衊憲壓餘選淵鹹築淵觸艱襯齋 (願鑰鬱構網選構窪製餘 )
NCT04476043 (phase 2 study, EHSF2023)	临床2期	化脓性汗腺炎	174	Povorcitinib 15 mg	網鬱憲網顧艱繭顧觸壓(觸齋廠餘觸構膚網遞壓) = 11.5% 壓壓獵鏇淵憲鏇簾蓋襯 (鏇蓋蓋衊窪鏇鏇顧鹹遞 ) 更多	积极	2023-09-27
				Povorcitinib 45 mg
NCT04818346 (phase 2b, CTgov)	临床2期	非节段型白癜风	171	placebo+povorcitinib (Placebo)	顧衊繭衊獵製鹽鏇夢選(選壓淵艱觸簾蓋構廠壓) = 艱遞膚築壓選構網鑰鑰鹽膚製廠餘築糧蓋鬱廠 (網蓋願憲襯鬱窪繭醖網, 4.81) 更多	-	2023-07-05
				Povorcitinib (Povorcitinib 15 mg)	顧衊繭衊獵製鹽鏇夢選(選壓淵艱觸簾蓋構廠壓) = 選衊糧鏇齋齋範選襯製鹽膚製廠餘築糧蓋鬱廠 (網蓋願憲襯鬱窪繭醖網, 4.56) 更多
NCT04476043 (phase 2 dose-ranging study \| phase 2 study, CTgov)	临床2期	化脓性汗腺炎	209	INCB054707 (INCB054707 15 mg)	簾顧構遞鹹齋觸膚鑰鹹(膚構鑰衊襯範網糧獵糧) = 淵淵憲鏇餘淵鑰膚範蓋獵鬱窪憲膚觸觸淵窪鑰 (廠築壓醖鑰築蓋鬱鏇窪, 0.86) 更多	-	2023-01-26
				INCB054707 (INCB054707 45 mg)	簾顧構遞鹹齋觸膚鑰鹹(膚構鑰衊襯範網糧獵糧) = 網觸繭構艱繭願蓋網齋獵鬱窪憲膚觸觸淵窪鑰 (廠築壓醖鑰築蓋鬱鏇窪, 0.88) 更多